X

Vous n'êtes pas connecté

Rubriques :

  - ZACKS.COM - All Stories - 02/Jul 13:28

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.

Articles similaires

Sorry! Image not available at this time

Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore

zacks.com - 03/Jul 12:42

EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.

Sorry! Image not available at this time

Two big reasons why buying Verona was crucial for Merck

wn.com - 09/Jul 17:04

Verona Pharma Plc (NASDAQ: VRNA) rallied about 20% on Wednesday after Merck & Co Inc (NYSE: MRK) said it will buy the UK-based biotech firm known for...

Sorry! Image not available at this time

Two big reasons why buying Verona was crucial for Merck

wn.com - 09/Jul 17:04

Verona Pharma Plc (NASDAQ: VRNA) rallied about 20% on Wednesday after Merck & Co Inc (NYSE: MRK) said it will buy the UK-based biotech firm known for...

Sorry! Image not available at this time

Best Momentum Stock to Buy for July 7th

zacks.com - 07/Jul 14:00

VRNA and EVLV made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 7, 2025.

Sorry! Image not available at this time

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

zacks.com - 10/Jul 13:50

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Sorry! Image not available at this time

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

zacks.com - 10/Jul 13:50

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Sorry! Image not available at this time

Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?

zacks.com - 01/Jul 13:33

INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.

Sorry! Image not available at this time

AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?

zacks.com - 08/Jul 14:43

AZN's oncology sales rise 13% in Q1 2025, driven by key drugs and new approvals. Can this momentum last?

Sorry! Image not available at this time

Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?

zacks.com - 11/Jul 12:19

MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.

Sorry! Image not available at this time

3 Wood Stocks Beating the Odds in a Tough Industry Climate

zacks.com - 08/Jul 16:08

More infrastructure spending, a focus on product innovation and efficient cost management are encouraging for the Zacks Building Products - Wood...

Les derniers communiqués